Below are some frequently asked questions. For all other investor enquiries please contact email@example.com. We commit to answering investor enquiries within 48 hours.
Trajan designs, manufactures and supplies a portfolio of products and services comprising precision consumable products, devices and solutions. These products and solutions are used in the analysis of biological, food, water and other environmental samples. Trajan has a pipeline of new technologies which includes micro-sampling devices, novel sample preparation chemistries and a portable modular analytical instrument system.
Trajan supplies a broad range of precise technical products and solutions to the analytical science sector, as well as having a range of new technologies in various stages of development. Key product categories include:
Trajan derives revenue from the sale of products, devices and solutions to a customer portfolio that includes the large multi-national original equipment manufacturers (OEMs) in the industry, pharmaceutical, food and contract research organisation (CRO) laboratories and scientific distribution companies.
The Company has a specialised approach, focusing on targeted segments where an analytical product or component has the potential to significantly impact data quality.
The ultimate end-users of Trajan’s products today are the laboratories performing testing for the food, beverage, environmental, biological, pharmaceutical and pathology industries.
Trajan’s research and development (R&D) begins with traditional in-house R&D. Trajan employs nearly 80 scientists and engineers. This is complemented by an array of strategic collaborations and alliances with industry and academia, while also accessing applicable government grant funding where available.
Trajan products possess precision, reproducible quality and consistency which enables end-users to achieve high standards of analytical performance. Trajan deeply understands the end-user applications and collaborates closely with customers.
The analytical science industry has an underlying growth projection of more than 5.1%, depending on the analytical technique or end-use market.
Trajan expects it will continue to achieve organic market share growth in excess of forecast industry growth through the continued introduction of its suite of extension and emerging technologies.
Trajan also has a track record of successful identification and integration of specialist capabilities via acquisition. The capital raised by the Company under the IPO will enable the continuation and potential acceleration of this strategy.
The payment of a dividend by Trajan is at the discretion of the Board and will depend upon a number of factors (many of which may be outside the control of Trajan and its Directors and management, and are not reliably predictable), including the general business environment, operating results, cash flows and financial condition of Trajan’s future funding requirements, capital management initiatives, taxation considerations, any contractual, legal or regulatory restrictions on the payment of dividends by Trajan, and any other factors the Directors may consider relevant.
While it is the aim of Trajan that, in the longer term, its financial performance and position will enable the payment of dividends, at the Prospectus Date, Trajan does not intend, nor expect to declare nor pay any dividends in the immediate foreseeable future, as Trajan’s focus will be to reinvest available funds in order to maximise its growth.
Trajan’s share registry is managed by Computershare. To access information on your shareholding please visit the Investor Centre or contact 1300 850 505 (within AU) or +61 (03) 9415 4000 (outside AU).
The predominant impact of the 2020 COVID-19 pandemic on the analytical science sector was disruption to supply chains, for example, delays in product deliveries to end-users. There was also uneven demand for products and services due to regional specific shutdowns and lockdowns.
Today, laboratories have become increasingly accustomed to operating in this disrupted environment and have established protocols to allow continuity of operations. In many cases, laboratories perform essential services and even where operations recorded lower processing volumes, a backlog of samples to be analysed built up and is expected to contribute to continued demand growth.
The pandemic is not expected to have a long-term effect on the fundamental growth drivers in the analytical science market as many pharmaceutical and biopharma companies are focusing on new drug development to combat the pandemic, which may contribute to unexpected growth in the chromatography and mass spectrometry markets.
If you can’t find what you’re looking for on our website we’re happy to answer any questions about our company and products. Please connect with us on firstname.lastname@example.org